Tremeau is focused on providing non-opioid pain treatments for well-defined patient populations, centering its lead clinical-stage product TRM-201 (rofecoxib), a COX-2 selective NSAID. TRM-201 is the company’s investigational formulation of the previously marketed VIOXX and has shown no effect on bleeding time in studies cited by the company. Tremeau highlights that rofecoxib demonstrated a reduced risk of gastrointestinal bleeding versus traditional NSAIDs in a controlled trial, while also acknowledging class-wide cardiovascular risks and the historical voluntary withdrawal of VIOXX in 2004. The company secured funding from Gurnet Point Capital to advance clinical development, including a planned Phase III registrational trial. The FDA agreed in an End of Phase II meeting that Tremeau established comparable exposure between TRM-201 and the prior VIOXX formulation, allowing progression to Phase III. Tremeau plans to initiate the registrational trial in early 2021. Wedbush PacGrow served as Tremeau’s investment advisor. Tremeau Pharmaceuticals is a Cambridge, Mass.-based pharmaceutical company focused on non-opioid pain treatments for rare diseases and other unique patient conditions with no approved therapies. Its lead candidate is TRM-201 (rofecoxib), a COX-2 selective NSAID with granted orphan designation for the treatment of hemophilic arthropathy. Rofecoxib is described as a non-narcotic analgesic that has no effect on bleeding time relative to placebo and was the only COX-2 selective NSAID approved in the U.S. to show a reduced risk of gastrointestinal bleeding versus a traditional NSAID in a controlled trial. Tremeau’s approach emphasizes mechanism of action, documented efficacy, and a clinically differentiated profile for acute and chronic pain in rare diseases. The company plans to develop and commercialize rofecoxib for the orphan indication and subsequent niche patient segments where it may offer a favorable benefit‑risk profile. Tremeau closed a $5.2M first equity round to advance its pipeline and is led by CEO Bradford C. Sippy.

Total raised

$5M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2018